Breaking Down Wuhan Keqian Biology Co.,Ltd Financial Health: Key Insights for Investors

Wuhan Keqian Biology (688526.SS) sits at an intriguing crossroads for investors: Q3 2025 revenue slipped to CNY 250.57 million (down 5.44% QoQ) while trailing twelve months sales reached CNY 1.01 billion-a 12.43% YoY rise against a full-year 2024 revenue of CNY 941.92 million (-11.48% YoY); profitability remains robust with 2024 net profit attributable of CNY 382.35 million and a striking net profit margin near 40.6%, supported by a gross margin of 61.74% and operating margin of 34.62% (TTM operating income CNY 340.07 million); the balance sheet shows a net cash position of CNY 1.30 billion (CNY 2.80 per share), virtually debt-free (debt-to-equity 0.00%) and a current ratio of 5.32, yet operating cash flow fell 27.02% to CNY 392.68 million and valuation metrics (trailing P/E 18.30, forward P/E 16.68, P/B 1.82, P/S ~7.5) place the shares above an intrinsic estimate of CNY 11.26 versus market CNY 15.62-highlighting both the risks from competitive pressures and disease-driven demand swings and the growth levers in a rising R&D spend (CNY 86.12 million, 9.14% of revenue) and an expanding pipeline of vaccines; read on to unpack the numbers, debt-free strength, cash-flow caveats and whether the current pricing leaves margin for upside.

Wuhan Keqian Biology Co.,Ltd (688526.SS) - Revenue Analysis

Wuhan Keqian Biology reported quarter and annual figures that show mixed momentum: a sequential decline in Q3 2025 but solid TTM growth versus the prior year. Key metrics and trend context are presented below.

• Q3 2025 revenue: CNY 250.57 million (down 5.44% vs. previous quarter)
• TTM revenue: CNY 1.01 billion (up 12.43% year-over-year)
• 2024 annual revenue: CNY 941.92 million (down 11.48% vs. 2023)
• Revenue per employee: ~CNY 1.10 million; total employees: 924
• Market capitalization: CNY 7.17 billion; Price-to-Sales (P/S): 7.07
• Revenue growth history: +6.27% in 2023; -9.22% in 2022

Contextual points for investor consideration:

• TTM expansion (+12.43% YoY) suggests recent recovery despite quarterly softness.
• High P/S (7.07) implies investor expectations of continued revenue growth or margin expansion.
• Revenue per employee (~CNY 1.10M) indicates operational productivity benchmarks versus peers.

Further background on strategy and corporate direction is available here: Mission Statement, Vision, & Core Values (2026) of Wuhan Keqian Biology Co.,Ltd.

Wuhan Keqian Biology Co.,Ltd (688526.SS) - Profitability Metrics

• High gross margin (61.74%) signals strong pricing power or low production costs relative to revenue.
• Operating margin of 34.62% on TTM operating income of CNY 340.07M implies robust core profitability before financing and taxes.
• Net profit decline of 3.43% to CNY 382.35M and EPS decreases (basic EPS -3.53%, adjusted diluted EPS -15.19%) point to either higher non-operating costs, tax impacts, share dilution effects, or fewer one-off gains in 2024.

• Investors should note the gap between basic EPS (0.82 CNY) and adjusted diluted EPS (0.67 CNY) as an indicator of the impact of non-recurring items and dilution on per-share returns.
• Strong margins provide a buffer against moderate revenue volatility, supporting free cash flow potential if working capital is managed.

Wuhan Keqian Biology Co.,Ltd (688526.SS) - Debt vs. Equity Structure

Wuhan Keqian Biology presents an unusually conservative capital structure characterized by negligible leverage and a strong liquidity profile. Key balance-sheet and coverage metrics highlight the company's ability to fund operations and growth from internal resources while maintaining a large cash buffer.

• Total debt: CNY 6.93 million
• Cash and cash equivalents: CNY 1.31 billion
• Net cash position: CNY 1.30 billion (CNY 2.80 per share)
• Debt-to-equity ratio: 0.00%
• Current ratio: 5.32
• Interest coverage ratio: 119.74

• Capital allocation flexibility: high, given net cash of CNY 1.30 billion.
• Low refinancing and interest-rate risk due to near-zero leverage.
• Potential investor considerations: conservative balance sheet supports dividends, buybacks, M&A, or R&D investment without immediate external financing.

For corporate purpose and strategic positioning details, see: Mission Statement, Vision, & Core Values (2026) of Wuhan Keqian Biology Co.,Ltd.

Wuhan Keqian Biology Co.,Ltd (688526.SS) - Liquidity and Solvency

• Short-term assets: CNY 2.6 billion vs. short-term liabilities: CNY 495.1 million
• Long-term assets: CNY 2.6 billion vs. long-term liabilities: CNY 85.1 million
• Operating cash flow: CNY 392.68 million (down 27.02%)
• Investment cash flow: CNY 96.59 million (positive)
• Financing cash flow: CNY -503.18 million
• Altman Z-Score: 8.87 (low bankruptcy risk)

• Liquidity outlook: Current liquidity appears robust given a current ratio comfortably above 1 (short-term assets vs. liabilities ~5.25x).
• Solvency outlook: Low long-term leverage with long-term assets far exceeding long-term liabilities supports solvency resilience.
• Cash-flow considerations: Declining operating cash flow (-27.02%) is the primary operational concern; positive investment cash flow and negative financing cash flow point to active capital allocation and deleveraging.

Wuhan Keqian Biology Co.,Ltd (688526.SS) - Valuation Analysis

Key market and valuation metrics for Wuhan Keqian Biology Co.,Ltd (688526.SS) provide a snapshot of how the market currently prices the business relative to earnings, book value, sales and cash flow.

• Market capitalization: CNY 7.40 billion
• Enterprise value (EV): CNY 6.10 billion
• Trailing P/E: 18.30
• Forward P/E: 16.68
• P/B: 1.82
• P/S: 7.53
• EV/EBITDA: 13.61
• EV/Free Cash Flow: 21.40
• Estimated intrinsic value: CNY 11.26 (implying ~27.90% overvaluation at current price CNY 15.62)
• Beta: 0.61 (lower volatility vs. market)

• Interpretation: multiples place the company in a premium bracket on sales and cash flow, while earnings multiples (trailing and forward P/E) are moderate - implying market pays for growth and stability rather than distressed value.
• Risk/volatility: beta 0.61 indicates returns historically less sensitive to market swings, which can appeal to more risk-averse investors.
• Valuation gap: the estimated intrinsic value (CNY 11.26) vs. market price (CNY 15.62) highlights a notable premium; investors should reconcile growth assumptions and margin/cash-flow forecasts before acting.

Further context on the company's background, mission and business model can be found here: Wuhan Keqian Biology Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Wuhan Keqian Biology Co.,Ltd (688526.SS) - Risk Factors

• Intensified market competition has led to declining revenue and profitability as peers and new entrants pursue price-led share gains.
• Fluctuations in livestock and poultry prices can compress producer margins, reduce demand for preventive biologics and impact order volumes.
• Major animal-disease outbreaks (e.g., avian influenza, African swine fever) create demand volatility: severe outbreaks can both spike and then sharply curtail recurring product demand depending on control measures.
• New product launches may fail to achieve projected adoption curves, delaying revenue recognition and ROI on R&D and commercialization spend.
• Rising industry competition and pricing pressure could further erode profit margins, particularly on legacy vaccines where differentiation is limited.
• Concentration risk: reliance on a single product segment or a few flagship SKUs exposes the company to sector-specific shocks and regulatory or market shifts.

• Operational and financial metrics to watch: gross margin trends, EBITDA margin, R&D-to-revenue ratio, receivables days, inventory turnover, and concentration of revenue by product/segment and by top customers.
• Regulatory and biosecurity monitoring is critical given the company's exposure to disease cycles and export/import controls that can change market access.
• Cash runway sensitivity: under scenarios of weaker sales or margin compression, monitor free cash flow and debt covenants for signs of financing stress.

Wuhan Keqian Biology Co.,Ltd (688526.SS) - Growth Opportunities

• R&D expense (latest period): CNY 86.12 million (9.14% of revenue).
• Implied total revenue (calculated from R&D %): CNY 942.3 million.
• R&D personnel increase: from 278 to 315 (net +37 staff), strengthening bench depth.
• Targeted product expansion: vaccines for pigs and dogs, plus broader veterinary biologicals.

• Product pipeline and differentiation: Expanding into pig and dog vaccines strengthens recurring-revenue potential and cross-sell opportunities within livestock and companion animal segments.
• R&D efficiency and scale: Maintaining R&D spend at CNY 86.12 million while increasing headcount implies a shift toward higher internal capability and potentially faster time-to-market for new biologics.
• Talent and capability build: +37 R&D staff increases throughput for discovery, validation, and regulatory filings-critical for biologics commercialization.
• Market expansion opportunities: Exploring new applications and geographies for veterinary biologicals can leverage existing production and regulatory know-how to diversify revenue streams.
• Strategic alignment with consumption trends: Focus on animal health is consistent with continued demand for animal protein production efficiency and growth in pet ownership/care.